

1 Article

# 2 CLOT STIFFNESS MEASURED BY SEER 3 SONORHEOMETRY AS A MARKER OF POOR 4 PROGNOSIS IN HOSPITALIZED COVID-19 PATIENTS

5

6 Francisco José López-Jaime\*, Sandra Martín-Téllez\*, Alberto Doblas-Márquez\*, Ignacio Márquez-Gómez†,  
7 José María Reguera-Iglesias‡, Manuel Isidro Muñoz-Pérez\*, Ihosvany Fernández-Bello‡, Adrián Montaña\*.

8 \*Unidad de Hemostasia y Trombosis, Hospital Universitario Regional de Málaga, IBIMA, Málaga, Spain;  
9 [franlopezjaime@gmail.com](mailto:franlopezjaime@gmail.com) (F.J.L.J.); [sandra.martint@gmail.com](mailto:sandra.martint@gmail.com) (S.M.-T); [albertodoblas93@gmail.com](mailto:albertodoblas93@gmail.com) (A.D.-M.);  
10 [misidro.munoz.sspa@juntadeandalucia.es](mailto:misidro.munoz.sspa@juntadeandalucia.es) (M.I.M.-P.)

11 †Servicio de Enfermedades Infecciosas, Hospital Universitario Regional de Málaga, Málaga, Spain;  
12 [nacho.marquez83@gmail.com](mailto:nacho.marquez83@gmail.com) (I.M.-G.); [jmreguera99@yahoo.com](mailto:jmreguera99@yahoo.com) (J.M.R.-I)

13 ‡Biopharm, Novo Nordisk, Madrid, Spain; [IHFE@novonordisk.com](mailto:IHFE@novonordisk.com) (I.F.-B)

14

15 Correspondence: [adrianmo18@gmail.com](mailto:adrianmo18@gmail.com) (A.M.) Tel.: + 34 951291085

16

## 17 SUMMARY:

18

19 **Background:** High incidence of life-threatening thrombotic complications is observed in severely ill  
20 COVID-19 patients. D-dimer may help evaluate disease severity and predict outcomes at hospital  
21 admission. However, its non-specificity and long analysis times strongly constrain its clinical value.  
22 Viscoelastic tests (VET) are widely available rapid point-of-care devices that have been shown to detect a  
23 hypercoagulable state (increased clot stiffness and fibrinolysis shutdown) as major contributors of the  
24 thrombotic complication in COVID-19. Nevertheless, based on the data obtained so far, definitive  
25 conclusions have not been drawn.

26 **Objectives:** We aim to evaluate the association between VET parameters, standard coagulation tests and  
27 inflammation markers assessed in COVID-19 patients at hospital admission with disease severity and  
28 outcomes.

29 **Patients/Methods:** A total of 69 COVID-19 patients requiring hospitalization were included in the study.  
30 The pro-inflammatory and pro-thrombotic state was analyzed by a panel of inflammation markers (IL-6,  
31 CRP, LDH, ferritin), routine coagulation tests (PT, aPTT, platelet count, fibrinogen, D-dimer) and a SEER  
32 sonorheometry VET profile (Quantra® System).

33 **Results:** Inflammatory markers IL-6, CRP, LDH and ferritin were elevated in a high percentage of patients  
34 (73.6%, 89.2%, 57.1% and 52.4%), as were coagulation-related parameters such as fibrinogen (81.4%) and  
35 D-dimer levels (66.2%). Quantra® analysis revealed increased clot stiffness (CS) in 34.8%, particularly due  
36 to increased fibrinogen contribution (FCS) in 63.7%. Increased clot stability to lysis (CSL) was observed  
37 in 32.4%. Age > 65 years, elevated values of fibrinogen, D-dimer, LDH, increased clot stiffness and  
38 resistance to clot lysis were significantly associated with worsening disease. The Quantra® FCS parameter  
39 showed a particularly high prognostic value in distinguishing patients with severe symptomatology.

40 **Conclusion:** The global study of hemostasis by the whole blood point-of-care Quantra® VET system may  
41 be a powerful tool for identifying poor prognosis in COVID-19 patients at hospital admission. In particular,  
42 FCS measured by Quantra® could be established as a plausible prognostic marker to aid the clinical  
43 management of COVID-19 patients.

44

45 **KEYWORDS:** Quantra, thrombosis, viscoelastic tests, COVID-19

46

47

48

49

50 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

51 **1. INTRODUCTION**

52

53 At the moment of writing this article, coronavirus disease 2019 (COVID-19) caused by severe acute  
54 respiratory syndrome coronavirus 2 (SARS-CoV-2) has already killed more than 3 million people  
55 worldwide [1]. The development of an extreme inflammatory response and prothrombotic state is  
56 associated with poor prognosis and remains the major cause of the high morbidity and mortality rate  
57 associated with this condition [2,3].

58 Previous studies on the hemostatic status of COVID-19 patients identified several parameters such as  
59 fibrinogen and D-dimer that could be established as markers of thrombotic risk and helped in the clinical  
60 management of patients [3–5]. Elevated D-dimer levels (>1000 ng/mL) have also been proposed as an  
61 indicator of risk for pulmonary embolism [6]. However, these parameters have drawbacks that affect their  
62 reliability and clinical use to predict outcomes in COVID-19. D-dimer in particular has important  
63 limitations that raises questions on its true prognostic value for thrombosis in COVID-19. Although highly  
64 elevated levels of D-dimer in COVID-19 have been attributed to acute lung injury with intra-alveolar fibrin  
65 deposition and subsequent breakdown of this extravascular fibrin, D-dimer values may be elevated for a  
66 variety of reasons and therefore increased values are not only indicative of increased thrombotic risk [7–  
67 10]. In addition, D-dimer requires a long time of analysis which together weaken its clinical value and  
68 reveals the need to identify new biomarkers that provide a rapid and effective assessment of thrombotic  
69 risk in COVID-19.

70 Viscoelastic tests (VET) are recognized powerful tools for the rapid identification and characterization  
71 of hypercoagulable state in infectious diseases and several groups have already evaluated the use of VET  
72 in COVID-19 patients [11,12]. In general, the available data indicate a high frequency of increased clot  
73 stiffness and fibrinolysis shutdown but with weak evidence on the association of this hypercoagulable  
74 profile with disease severity. Larger studies with larger numbers of patients are therefore needed to confirm  
75 these important findings.

76 Sonic Estimation of Elasticity by Resonance (SEER) sonorheometry (Quantra® system) is a novel  
77 ultrasound-based VET technology [13]. With this system, a hypercoagulable profile has been reported in  
78 hospitalized COVID-19 patients [14,15]. The objective of this study is to investigate whether the Quantra  
79 parameters, as well as a panel of inflammation markers and routine coagulation tests, are associated with  
80 disease severity and outcomes of hospitalized COVID-19 patients.

81

82 **2. MATERIALS AND METHODS**

83

84 *2.1 Patients and diagnosis criteria*

85

86 A total of 69 patients, positive for SARS-CoV-2 by PCR and hospitalized at the Regional University  
87 Hospital of Málaga were included in the study. All patients were over 18 years of age and none had any  
88 other hemostasis disorders. Immunocompromised patients, such as oncology patients on chemotherapy or  
89 those positive for HIV were also excluded from the study.

90 Patients were classified according to disease severity (critical, severe, and non-severe) based on the  
91 World Health Organization (WHO) criteria [16]. Briefly, critical COVID-19 patients were those who  
92 presented sepsis, septic shock or other conditions that required provision of life-sustaining therapies  
93 (mechanical ventilation or vasopressor therapy); severe were those with oxygen saturation <90% on room  
94 air or respiratory rate >30 breaths/min or with signs of severe respiratory distress including the need to use  
95 accessory muscles and the inability to formulate full sentences; and finally, the absence of any critical or  
96 severe COVID-19 criteria was considered as non-severe disease. Patients were also classified according to  
97 the presence or absence of adverse events, including the need for mechanical ventilation, development of  
98 encephalitis, thrombotic events, admission to ICU (intensive care unit) or death. The study was approved  
99 by the local ethical committee. Written informed consent was obtained from patients or legal guardians  
100 before inclusion.

101

102 *2.2 Inflammatory and procoagulant status*

103

104 Citrated, EDTA and non-anticoagulated blood samples were drawn on hospital admission and after  
 105 confirmation of SARS-CoV-2 infection. Quantra<sup>®</sup> Hemostasis Analyzer (HemoSonics, Charlottesville,  
 106 VA, USA) was used to evaluate the global viscoelastic hemostatic status of the patients. On this system,  
 107 QStat<sup>®</sup> and QPlus<sup>®</sup> cartridges were used to determine the following parameters: Clot Time (CT),  
 108 Heparinase Clot Time (CTH), Clot Time Ratio (CTR: CT/CTH), Clot Stiffness (CS), Fibrinogen  
 109 Contribution to Clot Stiffness (FCS), Platelet Contribution to Clot Stiffness (PCS), Clot Stability to Lysis  
 110 (CSL). Details of Quantra QPlus and QStat cartridges have been described previously [17,18]. Complete  
 111 blood count, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin  
 112 time (aPTT), D-dimer, fibrinogen, IL-6, ferritin, lactate dehydrogenase (LDH) and C-reactive protein  
 113 (CRP) were also determined.

114

115 *2.3 Statistical analysis*

116

117 The statistical software "SPSS statistics" (IBM) was used for the analysis. Comparison for qualitative  
 118 (Chi-square test or Fisher's Exact Test) and quantitative differences (Mann-Whitney U test) were applied.  
 119 Relationship between parameters at admission and disease severity or adverse events was assessed by ROC  
 120 curve analysis.

121

122

123 **3. RESULTS**

124

125 *3.1 Demographic and clinical characteristics of the patients*

126

127 Table 1 and supplementary file 1 show demographic and clinical characteristics of the patient cohort:  
 128 44.9% of patients developed non-severe disease, 39.1% severe disease and 16% critical disease. Compared  
 129 to non-severe patients, severe/critical patients were older, often female and had more diabetes and adverse  
 130 events. A total of 26.1% of the patients had an adverse event during hospital admission. Except for  
 131 encephalitis, all adverse events occurred in the severe/critical group.

132

133

134

**Table 1. Demographic and clinical characteristics of COVID-19 patients with non-severe disease versus severe/critical disease.**

	<b>Total</b> (N=69) N (%)	<b>Non-severe</b> (N=31) N (%)	<b>Severe/Critical</b> (N=38) N (%)	<b>P-value (*)</b>
<b>Age</b>				
>65 years	34 (49.3)	10 (32.3)	24 (63.1)	0.011
<65 years	35 (50.7)	21 (67.7)	14 (36.8)	
<b>Sex</b>				
Male	38 (55)	23 (74.2)	15 (39.5)	0.004
Female	31 (45)	8 (25.8)	23 (60.5)	
<b>Past medical history</b>				
Hypertension	32 (46.4)	11 (35.5)	21 (55.3)	0.101
Diabetes	19 (27.5)	4 (12.9)	15 (39.5)	0.014
Coronary heart disease	10 (14.5)	4 (12.9)	6 (15.8)	1.000
COPD	7 (10.1)	2 (6.5)	5 (13.2)	0.446
<b>Adverse event</b>				
Mechanical ventilation	18 (26.1)	1 (3.2)	17 (44.7)	<0.001
ICU admission	13 (18.8)	0 (0)	13 (34.2)	<0.001
Encephalitis	5 (7.2)	0 (0)	5 (13.2)	0.060
Thrombotic event	1 (1.4)	1 (3.2)	0 (0)	0.449
Death	3 (4.3)	0 (0)	3 (7.9)	0.247
	4 (5.8)	0 (0)	4 (10.5)	0.122

135

136

137

138

139

(\*) Non-severe vs. severe/critical by Chi-square test and Fisher's Exact Test. COPD: chronic obstructive pulmonary disease.

*3.2 Increased clot stiffness in patients with poor prognosis.*

140 As shown in Table 2, patients with adverse events showed significantly higher values of CRP, LDH,  
 141 fibrinogen, D-dimer and the Quantra clot stiffness parameter FCS.

142  
 143  
 144

**Table 2. Median of inflammation and tissue damage markers, coagulation and Quantra® parameters in patients with and without adverse events.**

	No adverse events		Adverse events		P-value (*)
	N	Median (IQR)	N	Median (IQR)	
<b>Inflammation and tissue damage</b>					
IL-6 (pg/mL)	38	16.7 (0 - 1874)	15	6.8 (0 - 88)	0.239
CRP (mg/L)	47	44.9 (0 - 236)	18	94.8 (23 - 174)	0.015
LDH (IU/L)	45	234 (125 - 404)	18	308.5 (100 - 1716)	0.024
Ferritin (ng/mL)	45	211 (87 - 847)	18	413.8 (39 - 1365)	0.726
<b>Coagulation</b>					
PT (sec)	51	11.6 (11 - 18)	18	12.1 (11 - 13)	0.897
aPTT (sec)	51	25.2 (18 - 30)	18	24.6 (20 - 27)	0.951
Fibrinogen (mg/dL)	44	554 (215 - 900)	15	730.7 (532 - 900)	0.022
Platelet count ( $\times 10^3/\mu\text{L}$ )	51	199 (130 - 401)	18	238 (133 - 479)	0.929
D-dimer ( $\mu\text{g/L}$ )	50	611 (175 - 9915)	17	824.5 (300 - 3406)	0.043
<b>Quantra®</b>					
CT (sec)	51	137 (93 - 179)	18	143.5 (125 - 159)	0.816
CTH (sec)	50	123 (86 - 152)	18	129.5 (110 - 160)	0.522
CS (hPa)	51	26 (11 - 47)	18	36.1 (19 - 62)	0.058
PCS (hPa)	51	22.8 (10 - 38)	18	30.9 (15 - 48)	0.063
FCS (hPa)	51	3.7 (1 - 12)	18	6.2 (4 - 14)	0.018
CSL (%)	26	98 (88 - 100)	11	100 (91 - 100)	0.169

IQR: interquartile range; (\*) Mann-Whitney U-test.

145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162

Table 3 shows the proportion of elevated levels of all assessed parameters, defined as the proportion above the upper limit of normal (ULN), in the total cohort as well as in patients who did not experience an adverse event and those who did. Inflammation and tissue damage markers were elevated in at least half of the patients: IL-6 in 73.6%, CRP in 89.2%, LDH in 57.1% and ferritin in 52.4%. Regarding coagulation parameters, shortened PT and aPTT clot times, i.e., below the lower limit of normal (LLN), were only observed in 0% and 14.5%, respectively. An elevated platelet count was only present in 8.7% of all patients. In contrast, fibrinogen and D-dimer were elevated in 81.4% and 66.2%, respectively. On the Quantra system, shortened CT and CTH clot times (below LLN) were only observed in 8.7% and 14.7%, respectively. Total clot stiffness (CS) was elevated in 34.8%, with an elevated PCS and FCS in 27.6% and 63.7%, respectively. A CSL value of 100% (suggesting absence of fibrinolysis) was observed in 32.4%.

**Table 3. Markers of inflammation and tissue damage, coagulation and Quantra parameters: proportion above upper limit of normal (ULN) or below the lower limit of normal (LLN) in COVID-19 patients with no adverse events versus those with adverse events. In the case of PT, aPTT, CT and CTH, the percentage of patients with times below the lower limit of normal values was considered.**

Test	ULN/ BLN	N/total (%)	No adverse events	Adverse events	P-value (*)
			N/total (%)	N/total (%)	
<b>Inflammation and tissue damage</b>					
IL-6 (pg/mL)	4.4	39/53 (73.6)	28/38 (73.7)	11/15 (73.3)	1.000
CRP (mg/L)	5.0	58/65 (89.2)	41/47 (87.2)	17/18 (94.4)	0.663
LDH (IU/L)	246	36/63 (57.1)	21/45 (46.7)	15/18 (83.3)	0.008
Ferritin (ng/mL)	388	33/63 (52.4)	22/45 (48.9)	11/18 (61.1)	0.380
<b>Coagulation</b>					
PT (sec)	10.0	0/69 (0)	0/51 (0)	0/18 (0)	1.000
aPTT (sec)	20.6	10/69 (14.5)	8/51 (15.7)	2/18 (11.1)	1.000
Platelet count ( $\times 10^3/\mu\text{L}$ )	450	6/69 (8.7)	5/51 (9.8)	1/18 (5.6)	1.000
Fibrinogen (mg/dL)	400	48/59 (81.4)	34/44 (77.3)	14/15 (93.3)	0.259
D-dimer ( $\mu\text{g/L}$ )	500	45/68 (66.2)	29/50 (58)	16/18 (88.9)	0.018
<b>Quantra®</b>					
CT (sec)	113	6/69 (8.7)	3/51 (5.9)	2/18 (11.1)	0.600
CTH (sec)	109	10/68 (14.7)	7/50 (14)	3/18 (16.7)	0.717
CS (hPa)	33.2	24/69 (34.8)	14/51 (27.4)	10/18 (55.6)	0.031


PCS (hPa)	29.8	19/69 (27.6)	11/51 (21.6)	8/18 (44.4)	0.074
FCS (hPa)	3.7	44/69 (63.7)	28/51 (54.9)	16/18 (88.9)	0.008
CSL (%)	100	12/37 (32.4)	5/26 (19.2)	7/11 (63.6)	0.018

(\*) Non-severe vs. severe/critical by Chi-square test and Fisher's Exact Test.

163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177

Only, LDH, D-dimer, the Quantra clot stiffness parameters (CS and FCS) and resistance to lysis (CSL) showed a significantly higher proportion of elevated values in COVID-19 patients with no adverse events compared with those with adverse events. Patients with elevated FCS values together with elevated D-dimer values were significantly associated with the presence of an adverse event ( $P<0.001$ ).

In predicting the severity of disease, the area under the curve (AUC) by ROC analysis was 0.720 with a 95% confidence interval of [0.546 – 0.895] ( $P=0.038$ ) for FCS; 0.581 [0.379 – 0.783] ( $P=0.443$ ) for LDH; 0.635 [0.439 – 0.831] ( $P=0.203$ ) for D-dimer; 0.673 [0.485 – 0.860] ( $P=0.104$ ) for CS and 0.538 [0.336 – 0.739] ( $P=0.722$ ) for CSL. In predicting the manifestation of an adverse event, the AUC was 0.715 [0.541 – 0.888] ( $P=0.047$ ) for FCS; 0.645 [0.440 – 0.849] ( $P=0.181$ ) for LDH; 0.562 [0.361 – 0.763] ( $P=0.567$ ) for D-dimer; 0.657 [0.451 – 0.863] ( $P=0.147$ ) for CS and 0.643 [0.422 – 0.863] ( $P=0.188$ ) for CSL. Thus, only FCS showed the highest significant AUC compared to the other variables such as D-dimer, as shown in figure 1 ( $P=0.003$ ).




178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192

**Figure 1. ROC analysis. A)** ROC curve of FCS and D-dimer at admission in predicting severity of disease. **B)** ROC curve of FCS and D-dimer at admission in predicting the manifestation of an adverse event.

### 3.3 Close interaction between procoagulant status and inflammation in COVID-19 patients.

FCS values showed a strong correlation with plasma fibrinogen ( $r=0.850$ ;  $P<0.001$ ). In turn, both parameters showed a moderate to strong correlation with CRP values (0.699;  $P<0.001$  for FCS and 0.803;  $P<0.011$  for plasma fibrinogen). Elevated FCS and plasma fibrinogen values were significantly associated with elevated CRP values ( $P=0.008$  and  $P<0.001$ , respectively) and IL-6 values ( $P=0.028$  and  $P<0.001$ , respectively). On the other hand, PCS correlated strongly with platelet count ( $r=0.752$ ;  $P<0.001$ ) (Figure 2).



193  
194  
195 **Figure 2. Scatter plots and Spearman correlation.** FCS vs. fibrinogen (left) and CRP (middle); PCS vs. platelet  
196 count (right).

#### 197 4. DISCUSSION

198  
199 We present the results of a pilot study in which we evaluated the use of global viscoelastic hemostatic  
200 analysis by sonorheometry (Quantra system) in COVID-19 patients on admission and the association of the  
201 Quantra parameters with disease severity and outcomes. Whole blood samples from 69 COVID-19 patients  
202 were analyzed using standard laboratory tests for coagulation, inflammatory and tissue damage markers  
203 and the Quantra Hemostasis Analyzer. Global hemostatic analysis by the Quantra revealed increased clot  
204 stiffness in a high number of COVID-19 patients, especially in those who experienced an adverse event  
205 during admission, such as the need for mechanical ventilation, development of encephalitis, thrombotic  
206 event, ICU admission or death. Particularly the FCS value was shown to indicate poor prognosis and could  
207 be of great use in the clinical management of these patients, both in triage and in the development of new  
208 therapeutic approaches.

209 Of the total cohort, 55.1% were classified as having severe/critical disease according to WHO criteria  
210 [16]. As expected, all patients who experienced an adverse event belonged to this group, except for one  
211 patient in the non-severe disease group who developed encephalitis. The most occurring event was the  
212 presence of ARDS observed in 18.8% of patients, who required mechanical ventilation. Consistent with  
213 previous studies, we observed that an age > 65 years was indicative of a worse prognosis [19,20]. Thus,  
214 patients with advanced age were more frequently observed in the severe/critical disease group. Other  
215 comorbidities such as diabetes were also associated with a worse prognosis as previously described [21,22].

216 We observed in our series a high proportion of patients with IL-6 and CRP values above the ULN. In  
217 support of our finding, these markers have been shown to be elevated in COVID-19 patients, especially in  
218 those with ARDS [5]. In fact, the group of Herold. et al. demonstrated the value of these parameters as  
219 predictors of the need for mechanical ventilation. Elevated fibrinogen levels were also associated with  
220 elevated Il-6 values, thus establishing a clear interaction between coagulation and inflammation, as reported  
221 in the study by Ranucci et al [14]. This is further evidence in support of the concept of immunothrombosis  
222 as a pathogenetic mechanism in COVID-19 [20]. A high percentage of patients in our cohort also showed  
223 LDH values above ULN, especially in those associated with worse prognosis, consistent with lung damage  
224 due to pneumonia caused by SARS-CoV-2 infection and which has been associated with increased patient  
225 mortality [23].

226 Regarding coagulation parameters, COVID-19 patients showed elevated levels of fibrinogen and D-  
227 dimer, the latter being mostly observed in patients who experienced an adverse event during admission.  
228 These results are also in agreement with those reported in the literature, which propose these factors as  
229 probably responsible for the thrombotic events that have been observed in COVID-19 patients [3,4].

230 VET analysis has also been proposed as a powerful tool for the study of the global hemostatic status  
231 of COVID-19 patients [24]. Especially, these studies have focused on the analysis of patients with poor  
232 prognosis such as those admitted to the ICU or with ARDS, revealing that VET analysis could be  
233 established as a promising tool to predict thrombotic complications and thus optimize the diagnosis and  
234 treatment of COVID-19 patients [25]. Our results showed that a high percentage of patients had altered  
235 parameters of clot stiffness, mainly due to the contribution of fibrinogen. Alterations in these parameters  
236 were significantly more prevalent in patients with an adverse event during admission. These results support  
237 previous studies suggesting that the hypercoagulability of COVID-19 patients is largely attributable to the  
238 contribution of fibrin and platelets to clot stability and stiffness [14].

239 As expected, platelet count and fibrinogen levels correlated positively with PCS and FCS values,  
240 respectively. However, despite the high correlation between platelet count and PCS, an elevated platelet  
241 count was observed in only 8.7% of patients, compared to 27.6% of patients with an elevated PCS. This  
242 result supports the evidence shown by Baryshnikova et al., that PCS is not only influenced by platelet count,  
243 but also by platelet functionality [26]. Furthermore, these findings highlight that platelet hyperreactivity  
244 plays a key role in the pathogenicity of severely ill COVID-19 patients, as previous studies have shown  
245 [27]. On the Quantra QStat, based on response in normal healthy individuals, the reference range is 93% to  
246 100%. In our cohort tested for CSL (n=37; 11 with adverse events), only 4 patients (1 with adverse events)  
247 showed a value below the lower limit of normal, suggesting hyperfibrinolysis. Although for the QStat CSL  
248 parameter a cut-off for fibrinolysis shutdown has not been determined, it is interesting to observe that the  
249 proportion with the maximum CSL value of 100% was significantly higher in the patients with an adverse  
250 event (63.6% vs. 19.2%;  $P=0.018$ ). This finding suggests the presence of fibrinolysis resistance in support  
251 of previous findings that attributed the hypercoagulability of COVID-19 patients to this phenomenon [28–  
252 30].

253 Many of these parameters, both inflammation and coagulation, have been proposed as promising  
254 prognostic markers to help us predict the risk of COVID-19 patients. In particular, many studies have  
255 focused on D-dimer as an indicator of poor prognosis [20,31]. However, the prognostic value of D-dimer  
256 has several limitations such as long analysis times, highlighting the need to identify other powerful markers.  
257 On the other hand, increased clot stiffness has been observed especially in patients with ARDS or ICU  
258 admission, revealing a possible association between these parameters and a worse prognosis of the disease  
259 [32]. Nevertheless, the prognostic value of clot stiffness measured by VET techniques has not yet been  
260 extensively studied. Our results demonstrate that clot stiffness parameters measured by Quantra® had a high  
261 prognostic value according to ROC analysis. In particular, fibrinogen contribution to clot stiffness (FCS)  
262 had the highest AUC compared to other parameters strongly associated with worse prognosis such as age  
263 or D-dimer. These findings highlight the potential use of this marker as predictor of poor prognosis in  
264 COVID-19 patients.

265 One of the limitations of our study is, however, that patients were analyzed only at the time of  
266 diagnosis. Previous studies have shown that the predictive value of D-dimer on the risk of death is much  
267 higher when measured just before the clinical outcome compared to the time of diagnosis, suggesting the  
268 importance of dynamically monitoring D-dimer levels to detect thrombotic complications and thus reduce  
269 the mortality rate of patients [20]. The results of our study, which found that FCS has a higher predictive  
270 value for an adverse event than D-dimer, indicate that FCS may also be an important parameter to monitor,  
271 especially in COVID-19 patients with elevated FCS at hospital admission. In this study we also observed  
272 that both elevated FCS and D-dimer were significantly more strongly associated with patients with a worse  
273 prognosis, suggesting the joint use of both parameters as a predictor of risk.

274 In summary, we can conclude from this study that the use of the sonorheometry VET technique allows  
275 a global analysis of the hemostatic status of COVID-19 patients in a rapid and efficient way, including clot  
276 stiffness parameters (CS, PCS, FCS, CSL) that are not routinely measured by standard laboratory tests.  
277 The implementation of this technique would allow for a more accurate diagnosis of patients on admission,  
278 helping in patient triage. By using this technique, we were able to detect that COVID-19 patients with  
279 higher clot stiffness showed a worse prognosis, especially due to the higher contribution of fibrinogen.  
280 Although further studies are needed to confirm these findings, these results show that the detection of FCS  
281 at admission could be of particular interest in the clinical management of COVID-19 patients and could  
282 also contribute to the development of new therapeutic strategies thanks to the numerous anticoagulant  
283 agents currently available.

284  
285 **AUTHOR CONTRIBUTIONS:** Conceptualization, F.J.L.-J, M.I.M.-P and I.F.-B; Methodology, F.J.L.-  
286 J, I.M.-G, I.F.-B and A.M; Software, F.J.L.-J and A.M; Validation, S.M.-T, I.F.-B and A.M; Formal  
287 analysis, F.J.L.-J, I.F.-B and A.M; Investigation, F.J.L.-J, S.M.-T, A.D.-M, J.M.R.-I and A.M; Data  
288 curation, A.D.-M, I.F.-B and A.M; Writing – original draft preparation, F.J.L.-J, I.F.-B and A.M, Writing  
289 – review and editing, all authors; Visualization, all authors; Supervision; F.J.L.-J and I.F.-B; Project  
290 administration, F.J.L.-J; Funding acquisition, F.J.L.-J; All authors have read and agreed to the published  
291 version of the manuscript.

292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350

**ACKNOWLEDGEMENTS:** The authors would like to thank to Beatriz Gago Caballero, Jessica Aguilera Rodríguez, Margarita López Quintero and Cristina Montes López from the Hospital Regional Universitario of Málaga, Spain, for their technical assistance. We would also like to thank all the nurses in the infectious diseases area of this hospital for their technical assistance. The study has been carried out in cooperation with Hemosonics but the company had no influence on decision to publish.

**CONFLICTS OF INTEREST:** The authors declare no conflict of interest.

**REFERENCES:**

1. World Health Organization WHO Coronavirus (COVID-19) Dashboard Available online: <https://covid19.who.int>.
2. Becker, R.C. COVID-19 update: Covid-19-associated coagulopathy. *J. Thromb. Thrombolysis* **2020**, *50*, 54–67, doi:10.1007/s11239-020-02134-3.
3. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 844–847, doi:10.1111/jth.14768.
4. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 1421–1424, doi:10.1111/jth.14830.
5. Herold, T.; Jurinovic, V.; Arnreich, C.; Lipworth, B.J.; Hellmuth, J.C.; von Bergwelt-Baildon, M.; Klein, M.; Weinberger, T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J. Allergy Clin. Immunol.* **2020**, *146*, 128–136.e4, doi:10.1016/j.jaci.2020.05.008.
6. Kwee, R.M.; Adams, H.J.A.; Kwee, T.C. Pulmonary embolism in patients with COVID-19 and value of D-dimer assessment: a meta-analysis. *Eur. Radiol.* **2021**, doi:10.1007/s00330-021-08003-8.
7. Hunt, B.J.; Levi, M. Re The source of elevated plasma D-dimer levels in COVID-19 infection. *Br. J. Haematol.* **2020**, *190*, doi:10.1111/bjh.16907.
8. Thachil, J. All those D-dimers in COVID-19. *J. Thromb. Haemost.* **2020**, *18*, 2075–2076, doi:10.1111/jth.14939.
9. Manfredini, R. D-dimer for the diagnosis of acute venous thromboembolism in the emergency department: a Janus-face marker. *Intern. Emerg. Med.* **2006**, *1*, 54–58, doi:10.1007/BF02934723.
10. Kabrhel, C.; Mark Courtney, D.; Camargo, C.A.; Plewa, M.C.; Nordenholz, K.E.; Moore, C.L.; Richman, P.B.; Smithline, H.A.; Beam, D.M.; Kline, J.A. Factors Associated With Positive D-dimer Results in Patients Evaluated for Pulmonary Embolism. *Acad. Emerg. Med.* **2010**, *17*, 589–597, doi:10.1111/j.1553-2712.2010.00765.x.
11. Harahsheh, Y.; Duff, O.C.; Ho, K.M. Thromboelastography Predicts Thromboembolism in Critically Ill Coagulopathic Patients\*. *Crit. Care Med.* **2019**, *47*, 826–832, doi:10.1097/CCM.0000000000003730.
12. Bareille, M.; Hardy, M.; Douxfils, J.; Roullet, S.; Lasne, D.; Levy, J.H.; Stépanian, A.; Susen, S.; Frère, C.; Lecompte, T.; et al. Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. *J. Clin. Med.* **2021**, *10*, 1740, doi:10.3390/jcm10081740.
13. Ferrante, E.A.; Blasier, K.R.; Givens, T.B.; Lloyd, C.A.; Fischer, T.J.; Viola, F. A Novel Device for the Evaluation of Hemostatic Function in Critical Care Settings. *Anesth. Analg.* **2016**, *123*, 1372–1379, doi:10.1213/ANE.0000000000001413.
14. Ranucci, M.; Ballotta, A.; Di Dedda, U.; Bayshnikova, E.; Dei Poli, M.; Resta, M.; Falco, M.; Albano, G.; Menicanti, L. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J. Thromb. Haemost.* **2020**, *18*, 1747–1751, doi:10.1111/jth.14854.
15. Masi, P.; Hékimian, G.; Lejeune, M.; Chommeloux, J.; Desnos, C.; Pineton De Chambrun, M.; Martin-Toutain, I.; Nieszkowska, A.; Lebreton, G.; Bréchet, N.; et al. Systemic Inflammatory Response Syndrome Is a Major Contributor to COVID-19–Associated Coagulopathy. *Circulation* **2020**, *142*, 611–614, doi:10.1161/CIRCULATIONAHA.120.048925.
16. World Health Organization COVID-19 Clinical management: living guidance Available online: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>.
17. Groves, D.S.; Winegar, D.A.; Fernandez, L.G.; Huffmyer, J.L.; Viola, F. Comparison of Coagulation Parameters in Arterial and Venous Blood in Cardiac Surgery Measured Using the Quantra System. *J. Cardiothorac. Vasc. Anesth.* **2019**, *33*, 976–984,

- 351 doi:10.1053/j.jvca.2018.08.201.  
352 18. Michelson, E.A.; Cripps, M.W.; Ray, B.; Winegar, D.A.; Viola, F. Initial clinical experience with  
353 the Quantra QStat System in adult trauma patients. *Trauma Surg. Acute Care Open* **2020**, *5*,  
354 e000581, doi:10.1136/tsaco-2020-000581.  
355 19. Alsahab, M.; Beishon, L.; Brown, B.; Burn, E.; Burton, J.K.; Cox, N.; Dani, M.; Elhadi, M.;  
356 Freshwater, S.; Gaunt, V.; et al. Age and frailty are independently associated with increased  
357 COVID-19 mortality and increased care needs in survivors: results of an international multi-centre  
358 study. *Age Ageing* **2021**, doi:10.1093/ageing/afab026.  
359 20. He, X.; Yao, F.; Chen, J.; Wang, Y.; Fang, X.; Lin, X.; Long, H.; Wang, Q.; Wu, Q. The poor  
360 prognosis and influencing factors of high D-dimer levels for COVID-19 patients. *Sci. Rep.* **2021**,  
361 *11*, 1830, doi:10.1038/s41598-021-81300-w.  
362 21. Guzik, T.J.; Mohiddin, S.A.; Dimarco, A.; Patel, V.; Savvatis, K.; Marelli-Berg, F.M.; Madhur,  
363 M.S.; Tomaszewski, M.; Maffia, P.; D'Acquisto, F.; et al. COVID-19 and the cardiovascular  
364 system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc. Res.* **2020**,  
365 *116*, 1666–1687, doi:10.1093/cvr/cvaa106.  
366 22. Guo, W.; Li, M.; Dong, Y.; Zhou, H.; Zhang, Z.; Tian, C.; Qin, R.; Wang, H.; Shen, Y.; Du, K.; et  
367 al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes.*  
368 *Metab. Res. Rev.* **2020**, *36*, doi:10.1002/dmrr.3319.  
369 23. Bartziokas, K.; Kostikas, K. Lactate dehydrogenase, COVID-19 and mortality. *Med. Clin. (Barc).*  
370 **2021**, *156*, 37, doi:10.1016/j.medcli.2020.07.043.  
371 24. Gergj, M.; Goodwin, A.; Freeman, K.; Colovos, C.; Volod, O. Viscoelastic hemostasis assays in  
372 septic, critically ill coronavirus disease 2019 patients: a practical guide for clinicians. *Blood*  
373 *Coagul. Fibrinolysis* **2021**, *32*, 225–228, doi:10.1097/MBC.0000000000000999.  
374 25. Hartmann, J.; Ergang, A.; Mason, D.; Dias, J.D. The Role of TEG Analysis in Patients with  
375 COVID-19-Associated Coagulopathy: A Systematic Review. *Diagnostics* **2021**, *11*, 172,  
376 doi:10.3390/diagnostics11020172.  
377 26. Baryshnikova, E.; Di Dedda, U.; Ranucci, M. A Comparative Study of SEER Sonorheometry  
378 Versus Standard Coagulation Tests, Rotational Thromboelastometry, and Multiple Electrode  
379 Aggregometry in Cardiac Surgery. *J. Cardiothorac. Vasc. Anesth.* **2019**, *33*, 1590–1598,  
380 doi:10.1053/j.jvca.2019.01.011.  
381 27. Manne, B.K.; Denorme, F.; Middleton, E.A.; Portier, I.; Rowley, J.W.; Stubben, C.; Petrey, A.C.;  
382 Tolley, N.D.; Guo, L.; Cody, M.; et al. Platelet gene expression and function in patients with  
383 COVID-19. *Blood* **2020**, *136*, 1317–1329, doi:10.1182/blood.2020007214.  
384 28. Ibañez, C.; Perdomo, J.; Calvo, A.; Ferrando, C.; Reverter, J.C.; Tassies, D.; Blasi, A. High D  
385 dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? *J.*  
386 *Thromb. Thrombolysis* **2021**, *51*, 308–312, doi:10.1007/s11239-020-02226-0.  
387 29. Görlinger, K.; Almutawah, H.; Almutawaa, F.; Alwabari, M.; Alsultan, Z.; Almajed, J.; Alwabari,  
388 M.; Alsultan, M.; Shahwar, D.; Yassen, K.A. The role of rotational thromboelastometry during the  
389 COVID-19 pandemic: a narrative review. *Korean J. Anesthesiol.* **2021**, *74*, 91–102,  
390 doi:10.4097/kja.21006.  
391 30. Meizoso, J.P.; Moore, H.B.; Moore, E.E. Fibrinolysis Shutdown in COVID-19: Clinical  
392 Manifestations, Molecular Mechanisms, and Therapeutic Implications. *J. Am. Coll. Surg.* **2021**,  
393 doi:10.1016/j.jamcollsurg.2021.02.019.  
394 31. Long, H.; Nie, L.; Xiang, X.; Li, H.; Zhang, X.; Fu, X.; Ren, H.; Liu, W.; Wang, Q.; Wu, Q. D-  
395 Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor  
396 Prognosis. *Biomed Res. Int.* **2020**, *2020*, 1–10, doi:10.1155/2020/6159720.  
397 32. Vlot, E.A.; Van den Dool, E.J.; Hackeng, C.M.; Sohne, M.; Noordzij, P.G.; Van Dongen, E.P.A.  
398 Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive  
399 care unit. *Thromb. Res.* **2020**, *196*, 1–3, doi:10.1016/j.thromres.2020.07.035.  
400  
401